Program
anti-TL1A monoclonal antibody, low dose
Also written as “anti-TL1A monoclonal antibody, medium dose” and “anti-TL1A monoclonal antibody, high dose”.
Its studies are mostly in Colitis, Ulcerative · Crohn Disease, led by Biocad.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Biocad | 22 open or running | phase 2since Jul 14, 2025 | Jul 14, 2025 | Jan 2027phase 2 · NCT07080034 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 14, 2025First studies: 2 phase 2 studiesFirst studyNCT07078994, NCT07080034
Ahead
- Jan 2027Primary completion: phase 2 study in Colitis, UlcerativeNCT07080034
- May 2027Primary completion: phase 2 study in Crohn DiseaseNCT07078994
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07080034Colitis, Ulcerative · Russia | 2 | Recruiting | Jan 2027 | 198 |
| NCT07078994Crohn Disease · Russia | 2 | Recruiting | May 2027 | 204 |
How it is read
Names in the registry
- “anti-TL1A monoclonal antibody, low dose”, 2 entries
- “anti-TL1A monoclonal antibody, medium dose”, 2 entries
- “anti-TL1A monoclonal antibody, high dose”, 2 entries
Conditions, from the studies’ own filings
- Colitis, Ulcerative, 1 study
- Crohn Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.